Download MendeleyStructure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases
Hamdouchi, C., Zhong, B., Mendoza, J., Collins, E., Jaramillo, C., De Diego, J.E., Robertson, D., Spencer, C.D., Anderson, B.D., Watkins, S.A., Zhang, F., Brooks, H.B.(2005) Bioorg Med Chem Lett 15: 1943-1947
- PubMed: 15780638
- DOI: https://doi.org/10.1016/j.bmcl.2005.01.052
- Primary Citation of Related Structures:
1YKR - PubMed Abstract:
Structure-based design approach was successfully used to guide the evolution of imidazopyridine scaffold yielding new structural class of highly selective inhibitors of cyclin dependent kinases that were able to form a new interaction with an identified residue of the protein, Lys89. Compounds from this series have shown no detectable effect when tested against a representative set of other serine/threonine kinases such as GSK3beta, CAMKII, PKA, PKC-alpha,beta,epsilon,gamma. Compound 2i inhibits proliferation in HCT 116 cells in tissue culture. Synthesis, co-crystal structure of CDK2 in complex with compound 2i, and preliminary SAR study are disclosed.
Organizational Affiliation:
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, IN 46285, United States. hamdouchi_chafiq@lilly.com
